CHEPLAPHARM Acquires Gemzar from Lilly

On December 16, 2024, CHEPLAPHARM successfully concluded the acquisition of Gemzar® from Eli Lilly and Company. The transaction, initiated on October 2, 2024, now enhances CHEPLAPHARM's oncology portfolio by integrating Gemzar®, a key chemotherapeutic agent. This acquisition covers worldwide commercial rights, excluding South Korea.

Gemzar® is utilized in treating various cancers, including non-small cell lung, urothelial, biliary tract, pancreatic, ovarian, cervical, and breast cancers. The purchase underscores CHEPLAPHARM's leadership in acquiring established pharmaceutical products. CEO Edeltraud Lafer expressed satisfaction with the swift transaction process and noted the continuity with former undertakings, like the Zyprexa® acquisition.

This addition aligns with CHEPLAPHARM's strategy of expanding its market presence in oncology, adding to its existing roster of brands such as Vesanoid®, Tarceva®, and Taxol®. The agreement also includes the transfer of intellectual property and product registrations.